JP2025510790A5 - - Google Patents
Info
- Publication number
- JP2025510790A5 JP2025510790A5 JP2024556474A JP2024556474A JP2025510790A5 JP 2025510790 A5 JP2025510790 A5 JP 2025510790A5 JP 2024556474 A JP2024556474 A JP 2024556474A JP 2024556474 A JP2024556474 A JP 2024556474A JP 2025510790 A5 JP2025510790 A5 JP 2025510790A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- composition according
- composition
- mbdb
- methylone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263325757P | 2022-03-31 | 2022-03-31 | |
| US63/325,757 | 2022-03-31 | ||
| US202263328343P | 2022-04-07 | 2022-04-07 | |
| US63/328,343 | 2022-04-07 | ||
| USPCT/US2022/074369 | 2022-08-01 | ||
| PCT/US2022/074369 WO2023015154A1 (en) | 2021-08-06 | 2022-08-01 | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders |
| US202363437000P | 2023-01-04 | 2023-01-04 | |
| US63/437,000 | 2023-01-04 | ||
| PCT/US2023/012196 WO2023191952A1 (en) | 2022-03-31 | 2023-02-02 | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025510790A JP2025510790A (ja) | 2025-04-15 |
| JP2025510790A5 true JP2025510790A5 (https=) | 2026-02-05 |
Family
ID=88203364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024556474A Pending JP2025510790A (ja) | 2022-03-31 | 2023-02-02 | 精神活性医薬品ならびに精神医学的および神経学的な病態および障害の治療のためのそれらの用途 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4499066A4 (https=) |
| JP (1) | JP2025510790A (https=) |
| KR (1) | KR20240165982A (https=) |
| CN (1) | CN119095593A (https=) |
| AU (1) | AU2023241546A1 (https=) |
| CA (1) | CA3254727A1 (https=) |
| IL (1) | IL315832A (https=) |
| MX (1) | MX2024012095A (https=) |
| TW (1) | TW202345789A (https=) |
| WO (1) | WO2023191952A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120379978A (zh) * | 2022-10-20 | 2025-07-25 | 创见疗法股份有限公司 | 苯乙胺和卡西酮及其立体异构体与其前体的制备 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996039133A1 (en) * | 1995-06-06 | 1996-12-12 | Neurobiological Technologies, Inc. | Novel n-substituted-2-amino-3',4'-methylene-dioxypropiophenones |
| US8575194B1 (en) * | 2004-08-31 | 2013-11-05 | Jack William Schultz | Treatment methods of cognitive, emotional and mental ailments and disorders |
| EP2931291B1 (en) * | 2012-12-11 | 2021-10-20 | The McLean Hospital Corporation | Xenon treatment as an adjunct to psychotherapy for psychiatric disorders |
| WO2017151980A1 (en) * | 2016-03-03 | 2017-09-08 | Segreti Louis M | Cannabis-based bioactive formulations and methods for use thereof |
| WO2021257500A1 (en) * | 2020-06-17 | 2021-12-23 | Lobe Sciences Ltd. | Methods and compositions for treating mild traumatic brain injury, post-traumatic stress disorder and mild traumatic brain injury with post traumatic stress disorder |
| JP2024512796A (ja) * | 2021-04-01 | 2024-03-19 | テラン バイオサイエンシーズ インク． | サイケデリック薬およびセロトニン受容体調節因子に関する方法と組成物 |
| MX2024001654A (es) * | 2021-08-06 | 2024-06-28 | Transcend Therapeutics Inc | Medicamentos psicoactivos y su uso para el tratamiento de enfermedades y trastornos psiquiatricos y neurologicos. |
| AU2022330718B2 (en) * | 2021-08-20 | 2026-02-19 | Pharmala Biotech Inc. | Compositions comprising non-racemic mixtures of (r)- and (s)-3,4-methylenedioxymethamphetamine or (r) and (s) n-methyl-1,3-benzodioxolylbutanamine and uses thereof |
| WO2023081899A1 (en) * | 2021-11-05 | 2023-05-11 | Terran Biosciences, Inc. | Isotopically enriched n-methyl-1,3-benzodioxolylbutanamine (mbdb) and stereoisomers thereof |
| EP4426685A4 (en) * | 2021-11-05 | 2026-01-07 | Terran Biosciences Inc | Isotopic salts, crystalline forms, stereoisomers of methylone and ethylone and their methods of use |
| CA3239514A1 (en) * | 2021-12-09 | 2023-06-15 | Matthew J. Baggott | Specialized combinations for mental disorders or mental enhancement |
-
2023
- 2023-02-02 KR KR1020247034657A patent/KR20240165982A/ko active Pending
- 2023-02-02 JP JP2024556474A patent/JP2025510790A/ja active Pending
- 2023-02-02 CN CN202380031652.9A patent/CN119095593A/zh active Pending
- 2023-02-02 WO PCT/US2023/012196 patent/WO2023191952A1/en not_active Ceased
- 2023-02-02 EP EP23781540.2A patent/EP4499066A4/en active Pending
- 2023-02-02 CA CA3254727A patent/CA3254727A1/en active Pending
- 2023-02-02 IL IL315832A patent/IL315832A/en unknown
- 2023-02-02 AU AU2023241546A patent/AU2023241546A1/en active Pending
- 2023-02-06 TW TW112104131A patent/TW202345789A/zh unknown
-
2024
- 2024-09-30 MX MX2024012095A patent/MX2024012095A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bhatt et al. | Targeting inflammation: a potential approach for the treatment of depression | |
| Ahmadpanah et al. | Crocus sativus L.(saffron) versus sertraline on symptoms of depression among older people with major depressive disorders–a double-blind, randomized intervention study | |
| Hickie et al. | Novel melatonin-based therapies: potential advances in the treatment of major depression | |
| Banerjee et al. | Chronic administration of bacopa monniera increases BDNF protein and mRNA expressions: a study in chronic unpredictable stress induced animal model of depression | |
| JP2024530007A5 (https=) | ||
| Aricioğlu et al. | NLRP1-mediated antidepressant effect of ketamine in chronic unpredictable mild stress model in rats | |
| Cao et al. | Mechanistic studies of gypenosides in microglial state transition and its implications in depression-like behaviors: role of TLR4/MyD88/NF-κB signaling | |
| JP2025510790A5 (https=) | ||
| RU2020125170A (ru) | Композиции и способы улучшения биодоступности 5-гидрокситриптофана | |
| BR112023023030A2 (pt) | Composições e métodos para o tratamento de depressão | |
| Halaris et al. | The glutamatergic system in treatment-resistant depression and comparative effectiveness of ketamine and esketamine: role of inflammation? | |
| JP2021511365A5 (https=) | ||
| Abdallah et al. | RETRACTED: Double‐blind, randomized, placebo‐controlled pilot study of the phosphodiesterase‐3 inhibitor cilostazol as an adjunctive to antidepressants in patients with major depressive disorder | |
| Zhao et al. | Nootkatone improves chronic unpredictable mild stress-induced depressive-like behaviors by repressing NF-κB/NLRP3-mediated neuroinflammation | |
| JP2022553569A5 (https=) | ||
| JP2023526304A (ja) | コロナウイルス感染症治療のためのｔｌｒ７／８拮抗薬 | |
| Tian et al. | Effects of Bufei Yishen granules combined with acupoint sticking therapy on pulmonary surfactant proteins in chronic obstructive pulmonary disease rats | |
| Chen et al. | Antidepressant-like effect of 3-n-butylphthalide in rats exposed to chronic unpredictable mild stress: modulation of brain-derived neurotrophic factor level and mTOR activation in cortex | |
| JP2025504984A5 (https=) | ||
| Yoshino et al. | Endothelial nitric oxide synthase in rat brain is downregulated by sub-chronic antidepressant treatment | |
| Girish | A novel atypical antidepressant drug: Agomelatine–A review | |
| NO20045552L (no) | Kombinasjonsterapi hvori en serotonin gjenopptaksinhibitor anvendes | |
| JP2011516604A (ja) | 鬱病患者の自殺行動の予防治療のためのミルナシプラン塩酸塩の（１ｓ，２ｒ）鏡像異性体の使用 | |
| JP2007509877A5 (ja) | ウチワサボテン植物の部分および／またはそれからの抽出物を含むうつ病治療剤 | |
| Herrick et al. | Insomnia and depression: A reciprocal relationship |